A Phase II Study of Lenalidomide Alone in Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes With Chromosome 5 Abnormalities

This phase II study assessed the efficacy and safety of lenalidomide in patients with relapsed/refractory acute myeloid leukemia (N = 18) and high-risk myelodysplastic syndrome (N = 9) with chromosome 5 abnormalities. The overall complete remission rate with or without platelet recovery was 7% (2/27...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Chen, Yiming, Kantarjian, Hagop, Estrov, Zeev, Faderl, Stefan, Ravandi, Farhad, Rey, Kristy, Cortes, Jorge, Borthakur, Gautam
Formato: Artigo
Lenguaje:Inglês
Publicado: 2012
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4103411/
https://ncbi.nlm.nih.gov/pubmed/22579233
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2012.04.001
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares